Time filter

Source Type

Kao S.C.H.,Asbestos Diseases Research Institute | Harvie R.,Bill Walsh Cancer Research Laboratories | Harvie R.,University of Sydney | Paturi F.,Bill Walsh Cancer Research Laboratories | And 12 more authors.
Lung Cancer | Year: 2012

There is a need for new treatment strategies and prognostic markers for the management of malignant mesothelioma (MM). The activity of thalidomide/cisplatin/gemcitabine (arm A) or thalidomide alone (arm B) was investigated in two parallel phase II studies in patients with advanced MM, using 6 month progression free survival (PFS) as the principal end-point. The predictive role of pre-treatment and 8 week follow-up serum C-reactive protein (CRP), interlukin-6 (IL-6), interlukin-6 soluble receptor (sIL-6R), mesothelin (SMRP) and vascular endothelial growth factor (VEGF) was also assessed. The proportion of patients with stable disease for >6 months was similar in both studies (arm A 35%, arm B 29%) and toxicity was mainly grade I/II. In univariate analyses only pre-treatment VEGF and CRP were correlated with survival. At 8 weeks post treatment, increased survival was found with low (median) VEGF and CRP (P< 0.05). Change in VEGF over the first 8 weeks of treatment was also predictive for survival (P< 0.05). When pre-treatment VEGF was >median, decreasing VEGF was associated with increased survival (P< 0.05). In conclusion, thalidomide alone, or in combination with cisplatin/gemcitabine, controlled disease for >6 months in ∼30% of patients. Patients with decreasing VEGF during treatment had longest survival. Pre-treatment VEGF or CRP and early change in VEGF on treatment may predict treatment benefit and should be examined in future studies. © 2011 Elsevier Ireland Ltd.

Loading Bill Walsh Cancer Research Laboratories collaborators
Loading Bill Walsh Cancer Research Laboratories collaborators